Avoid common mistakes on your manuscript.
Erratum to: Invest New Drugs
DOI 10.1007/s10637-011-9687-4
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found at http://dx.doi.org/10.1007/s10637-011-9687-4.
Rights and permissions
About this article
Cite this article
Bodoky, G., Timcheva, C., Spigel, D.R. et al. Erratum to: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs 30, 1272–1273 (2012). https://doi.org/10.1007/s10637-011-9713-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-011-9713-6